Roche's $7.1B bet on Roivant drug; ADCs and other #ESMO23 dispatch; Highlights from Alzheimer's confab; Q3 pharma drama; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Between earnings season, conferences and a busy congressional schedule, there is truly no boring day here at Endpoints. This week, we bring you our full ESMO and CTAD coverage, key takeaways from Q3 results, as well as the splashy Roche deal and a play-by-play look at how Bristol Myers Squibb ended up buying Mirati.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.